Indikace a využití

Irritable bowel syndrome

• Zkoumán Solabegron [4]

Treatment of obesity and type 2 diabetes

• Since 1990s in developmental stages within many large pharmaceutical companies
• Without successfully delivering an anti-obesity product to the market [1]
• 2004-2008 phase 2 clinical trials were performed
• Development of Mirabegron for type two diabetes was interrupted [1]

Srdeční selhání

• Efficacy of Mirabegron in prevention of heart failure
• In 2018 the study is ongoing and it's expected to conclude in 2020 [1]

Overactive bladder (OAB) syndrome

Mirabegron (Myrbetriq, Betmiga)

• Selective ß3-AR agonist
• 2012 Mirabegron was the first beta 3-AR agonist to be approved in the United States and Europe
• 2018 only one beta 3-AR agonist is approved as a medicine
• By stimulation of ß3-AR
• The contraction of the smooth muscles of the bladder is decreased (m. detrusor)
• Bladder can store more volume of urine at a given time
• Decreasing the frequency of the non-voiding contractions [1]

Vibegron

• 2018 in phase 3 clinical trial to treat OAB [1]
• 2011 Merck & Co. entered clinical trials with Vibegron with the indication for OAB [1]

Solabegron

• 2018 in phase 2b clinical trials to treat OAB in women
• 2018 in phase 1 clinical trials in men to treat OAB [1]